

# Michal Tendera

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10679687/publications.pdf>

Version: 2024-02-01

64  
papers

76,427  
citations

46918

47  
h-index

102304

66  
g-index

68  
all docs

68  
docs citations

68  
times ranked

48587  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2012, 33, 1787-1847. | 1.0  | 5,233     |
| 2  | ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. <i>European Heart Journal</i> , 2012, 33, 2569-2619.  | 1.0  | 5,034     |
| 3  | 2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Heart Journal</i> , 2014, 35, 2541-2619.  | 1.0  | 4,141     |
| 4  | Myocardial infarction redefined—a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2000, 36, 959-969.   | 1.2  | 4,090     |
| 5  | 2013 ESC guidelines on the management of stable coronary artery disease. <i>European Heart Journal</i> , 2013, 34, 2949-3003.  | 1.0  | 3,915     |
| 6  | 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. <i>European Heart Journal</i> , 2014, 35, 2733-2779.   | 1.0  | 3,469     |
| 7  | Guidelines on the management of valvular heart disease (version 2012). <i>European Heart Journal</i> , 2012, 33, 2451-2496.  | 1.0  | 3,465     |
| 8  | Effect of Carvedilol on Survival in Severe Chronic Heart Failure. <i>New England Journal of Medicine</i> , 2001, 344, 1651-1658.   | 13.9 | 2,909     |
| 9  | ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). <i>European Heart Journal</i> , 2011, 32, 1769-1818.  | 1.0  | 2,767     |
| 10 | Third Universal Definition of Myocardial Infarction. <i>Circulation</i> , 2012, 126, 2020-2035.  | 1.6  | 2,722     |
| 11 | Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). <i>European Heart Journal</i> , 2010, 31, 2501-2555.  | 1.0  | 2,649     |
| 12 | Guidelines on the diagnosis and management of acute pulmonary embolism. <i>European Heart Journal</i> , 2008, 29, 2276-2315.   | 1.0  | 2,645     |
| 13 | Third Universal Definition of Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 60, 1581-1598.   | 1.2  | 2,558     |
| 14 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. <i>European Journal of Heart Failure</i> , 2012, 14, 803-869.  | 2.9  | 2,307     |
| 15 | 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Heart Journal</i> , 2018, 39, 763-816.   | 1.0  | 2,305     |
| 16 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.  | 1.0  | 2,246     |
| 17 | 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. <i>European Heart Journal</i> , 2013, 34, 2281-2329.  | 1.0  | 2,176     |
| 18 | 2014 ESC/EACTS Guidelines on myocardial revascularization. <i>European Journal of Cardio-thoracic Surgery</i> , 2014, 46, 517-592.   | 0.6  | 2,164     |

| #  | ARTICLE   | IF   | CITATIONS |
|----|---|------|-----------|
| 19 | Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation. <i>European Heart Journal</i> , 2008, 29, 2909-2945.   | 1.0  | 2,128     |
| 20 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008. <i>European Journal of Heart Failure</i> , 2008, 10, 933-989.   | 2.9  | 1,893     |
| 21 | 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2006, 28, 1462-1536.   | 1.0  | 1,617     |
| 22 | ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2011, 32, 2851-2906. | 1.0  | 1,394     |
| 23 | Guidelines on the management of valvular heart disease (version 2012). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S1-S44.   | 0.6  | 1,313     |
| 24 | The perindopril in elderly people with chronic heart failure (PEP-CHF) study. <i>European Heart Journal</i> , 2006, 27, 2338-2345.  | 1.0  | 1,280     |
| 25 | Effect of Carvedilol on the Morbidity of Patients With Severe Chronic Heart Failure. <i>Circulation</i> , 2002, 106, 2194-2199.   | 1.6  | 1,132     |
| 26 | Fourth Joint Task Force of the European Society of Cardiology and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited) <i>Tj ETQq0 0 OrgBT /Overdo</i> 10 T  |      |           |
| 27 | Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008, 372, 807-816.   | 6.3  | 934       |
| 28 | Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Heart Journal</i> , 2009, 30, 2769-2812.  | 1.0  | 735       |
| 29 | Editor's Choice " 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 55, 305-368.   | 0.8  | 734       |
| 30 | Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial. <i>Lancet, The</i> , 2008, 372, 817-821.   | 6.3  | 694       |
| 31 | Facilitated PCI in Patients with ST-Elevation Myocardial Infarction. <i>New England Journal of Medicine</i> , 2008, 358, 2205-2217.   | 13.9 | 596       |
| 32 | Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. <i>European Heart Journal</i> , 2012, 33, 2831-2840.  | 1.0  | 560       |
| 33 | Efficacy of ivabradine, a new selective If inhibitor, compared with atenolol in patients with chronic stable angina. <i>European Heart Journal</i> , 2005, 26, 2529-2536.   | 1.0  | 502       |
| 34 | Expert consensus document on $\beta$ -adrenergic receptor blockers The Task Force on Beta-Blockers of the European Society of Cardiology. <i>European Heart Journal</i> , 2004, 25, 1341-1362.  | 1.0  | 465       |
| 35 | Prognostic Impact of Plasma N-Terminal Pro-Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure. <i>Circulation</i> , 2004, 110, 1780-1786.   | 1.6  | 282       |
| 36 | Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. <i>European Journal of Anaesthesiology</i> , 2010, 27, 92-137.  | 0.7  | 263       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Effects of Initiating Carvedilol in Patients With Severe Chronic Heart Failure. JAMA - Journal of the American Medical Association, 2003, 289, 712.   | 3.8 | 261       |
| 38 | 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Journal of Cardio-thoracic Surgery, 2018, 53, 34-78.  | 0.6 | 261       |
| 39 | Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2 <sup>°</sup> P-TIMI 50 trial. Lancet, The, 2012, 380, 1317-1324.  | 6.3 | 202       |
| 40 | Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. European Heart Journal, 2009, 30, 2337-2345. | 1.0 | 192       |
| 41 | Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. Lancet, The, 2017, 389, 1799-1808.  | 6.3 | 174       |
| 42 | ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD – Summary. Diabetes and Vascular Disease Research, 2014, 11, 133-173.  | 0.9 | 173       |
| 43 | Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure. Journal of the American College of Cardiology, 2004, 43, 1423-1429.  | 1.2 | 132       |
| 44 | Design of the Reduction of Events with Darbeoetin alfa in Heart Failure (RED <sup>2</sup> CHF): a Phase III, anaemia correction, morbidity – mortality trial. European Journal of Heart Failure, 2009, 11, 795-801.   | 2.9 | 107       |
| 45 | NT-proBNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-proBNP substudy. European Journal of Heart Failure, 2004, 6, 343-350.   | 2.9 | 85        |
| 46 | β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. European Heart Journal, 2019, 40, 1399-1407.   | 1.0 | 66        |
| 47 | Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. European Heart Journal, 2020, 41, 347-356.   | 1.0 | 55        |
| 48 | Geographical variations in the prevalence and management of cardiovascular risk factors in outpatients with CAD: Data from the contemporary CLARIFY registry. European Journal of Preventive Cardiology, 2015, 22, 1056-1065.   | 0.8 | 50        |
| 49 | Epidemiology, treatment, and guidelines for the treatment of heart failure in Europe. Country Review Ukraine, 2005, 7, J5-J9.   | 0.8 | 41        |
| 50 | Treatment of chronic heart failure with carvedilol in daily practice: The SATELLITE survey experience. International Journal of Cardiology, 2007, 122, 149-155.   | 0.8 | 40        |
| 51 | Rationale, design, and baseline characteristics of the <sc>CLARIFY</sc> registry of outpatients with stable coronary artery disease. Clinical Cardiology, 2017, 40, 797-806.  | 0.7 | 40        |
| 52 | Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 203-212.   | 1.1 | 37        |
| 53 | Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica 2012. Revista Espanola De Cardiología, 2012, 65, 938.e1-938.e59.  | 0.6 | 31        |
| 54 | Inadequate heart rate control despite widespread use of beta-blockers in outpatients with stable CAD: findings from the international prospective CLARIFY registry. International Journal of Cardiology, 2014, 176, 119-124.  | 0.8 | 30        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 55 | Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 426-436.   | 0.8 | 21        |
| 56 | High-Sensitivity Troponin I in Stable Patients with Atherosclerotic Disease in the TRA 2 <sup>Â</sup> P - TIMI 50 Trial. <i>Clinical Chemistry</i> , 2017, 63, 307-315.  | 1.5 | 19        |
| 57 | GuÃa de prÃctica clÃnica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboraciÃn con la European Association for the Study of Diabetes. <i>Revista Espanola De Cardiologia</i> , 2014, 67, 136.e1-136.e56.          | 0.6 | 15        |
| 58 | Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. <i>International CLARIFY Registry. PLoS ONE</i> , 2015, 10, e0125164.  | 1.1 | 15        |
| 59 | Quality of Life With Ivabradine in Patients With Angina Pectoris. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 31-38.  | 0.9 | 15        |
| 60 | A randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of Trimetazidine in patients with angina pectoris having been treated by percutaneous coronary intervention (ATPCI) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 |     |           |
| 61 | Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. <i>European Heart Journal Quality of Care &amp; Clinical Outcomes</i> , 2021, 7, 287-294.  | 1.8 | 3         |
| 62 | Future Directions:What Data Do We Need?. , 2006, 43, 106-111.  |     | 2         |
| 63 | GuÃade prÃctica clÃnica sobre el tratamiento de las valvulopatÃas (versiÃn 2012). <i>Revista Espanola De Cardiologia</i> , 2013, 66, 131.e1-131.e42.   | 0.6 | 2         |
| 64 | The role of imaging in coronary artery disease - What do the ESC guidelines say. <i>Cor Et Vasa</i> , 2015, 57, e405-e407.   | 0.1 | 0         |